ClinicalTrials.gg
CompletedNCT00775437Updated Jan 26, 2016Results posted

Active Juvenile Idiopathic Arthritis (JIA) Compassionate Use

A Phase 3 interventional study of Adalimumab in Juvenile Idiopathic Arthritis, sponsored by AbbVie (prior sponsor, Abbott). Completed. Open to participants aged 2 Years to 4 Years. Per ClinicalTrials.gov, last updated 2016-01-26.

Sponsored by AbbVie (prior sponsor, Abbott) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
2 Years to 4 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 10 studies in Arthritis, Juvenile by AbbVie — 2 open to participants now, 3 under way, 2 of them phase 3. Arthritis, Juvenile · AbbVie.

Started
2009
the only one that year
Phase 3
4 of 10
2 open now
Registered
1st of 10
by date

Among the 10 studies in Arthritis, Juvenile by AbbVie, this one is the only one that started in 2009, is one of 4 in phase 3, and was the 1st registered.

Arthritis, Juvenile

366 studies on the registry are indexed under Arthritis, Juvenile; 101 are open to participants now.

Browse Arthritis, Juvenile studies →

Open to participants now

2 of the 10 studies in Arthritis, Juvenile by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 68 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 49 (72%) stop at 75 or younger; 64 take children under 18; 11 take healthy volunteers.

This study: 2 Years to 4 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Arthritis, Juvenile by AbbVie, or all of them as a file.
02

Study summary

The main objective of this study is to evaluate the safety of adalimumab in patients 2 to \< 4 years of age or ≥ 4 years of age weighing \< 15 kg, with moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) or polyarticular course JIA.

03

Conditions studied

  • Juvenile Idiopathic Arthritis

Browse trials for

Keywords

  • juvenile idiopathic arthritis
  • compassionate use
  • open label
04

Who can participate

Ages eligible
2 Years to 4 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A parent or guardian has voluntarily signed and dated an form, approved by an Institutional Review Board (IRB)/Independent Ethics Committee (IEC), after the nature of the study has been explained and the subject's parent or legal guardian has had the opportunity to ask questions. The informed consent must be signed before any study-specific procedures are performed or before any medication is discontinued for the purpose of this study. The parent must also be willing to comply with all the requirements of this study protocol.
  2. Subject has a disease diagnosis of moderately to severely active polyarticular or polyarticular course juvenile idiopathic arthritis (JIA; defined as arthritis affecting > = 5 joints at the time of treatment initiation). This corresponds to the International League of Associations for Rheumatology categories of polyarticular rheumatoid factor positive (RF+), polyarticular Rheumatoid factor negative (RF-) disease, and extended oligoarthritis disease.
  3. Subject must be aged 2 to \< 4 years old with moderately to severely active polyarticular JIA or polyarticular course JIA or age 4 or greater weighing \< 15 kg with moderately to severely active polyarticular JIA or polyarticular course JIA, per International League of Associations for Rheumatology (ILAR) criteria.
  4. Subject is judged to be in generally good health as determined by the Investigator based upon the results of medical history, laboratory profile, and physical examination performed at Screening and confirmed at Baseline. This includes, but is not limited to, a normal cardiopulmonary and normal neurological exam result.
  5. Parent or legal guardian must be able and willing to administer subcutaneous (SC) injections or have a qualified person available to administer SC injections.
  6. Parent or legal guardian must be willing to actively supervise storage and administration of study drug and to ensure that the time of each dose is accurately recorded in the subject's diary.
  7. Subject must have negative purified protein derivative (PPD) test (or equivalent) at Screening. If subject has a positive (greater than or equal to 5mm induration) PPD test result, a chest x-ray (posterior-anterior [PA] and lateral view) must be performed. If subject has a positive test (or equivalent), has had a past ulcerative reaction to PPD placement, and/or a chest x ray consistent with tuberculosis [TB] exposure, subject may not be enrolled into the study.
  8. For subjects in the European Union [EU], subject must have previously failed, had an insufficient response, or have been intolerant to at least one Disease-Modifying Anti Rheumatic Drug (DMARD).

Exclusion criteria

Exclusion Criteria:

  1. Subject has had prior exposure to Tysabri® (natalizumab) or Raptiva® (efalizumab) or any other biologic therapy, such as Orencia® (abatacept), Kineret® (anakinra), Actemra® (tocilizumab), Rituxan® (rituximab). Any previous use of anti-tumor necrosis factor [TNF] agents, including Enbrel® (etanercept), Remicade® (infliximab), Cimzia® (certolizumab pegol), Simponi® (golimumab), and adalimumab is also prohibited.
  2. Infection(s) requiring treatment with intravenous (IV) anti-infectives within 30 days prior to Baseline Visit or oral anti-infectives within 14 days prior to the Baseline Visit.
  3. Subject has undergone joint surgery within the preceding two months of the Screening Visit (at joints to be assessed within the study).
  4. Subject has a previous diagnosis of a condition that could cause arthritis other than polyarticular JIA.
  5. Subject has a history of an allergic reaction or significant sensitivity to constituents of the study drug, adalimumab.
  6. Subject has been treated with any drug of chemical or biologic nature within a minimum of 30 days or 5 half lives (whichever is longer) of the drug prior to Baseline visit. Should these biologics become approved, they would continue to be excluded.
  7. Subject has a poorly controlled medical condition, such as uncontrolled diabetes, unstable heart disease, recent cerebrovascular accidents, seizure disorder, and any other condition which, in the opinion of the Investigator, would put the subject at risk by participation in the study.
  8. Subject has a history of hematologic (e.g., severe anemia, leukopenia, thrombocytopenia, a clotting disorder), renal, liver disease (e.g., fibrosis, cirrhosis, hepatitis), or active gastroenteric ulcer.
  9. Subject is considered by the Investigator, for any reason, to be an unsuitable candidate for the study.
  10. Subject has evidence of active TB infection.
  11. Subject has history of moderate to severe congestive heart failure ( [NYHA] class III or IV), recent cerebrovascular accident or thrombotic event and any other condition which, in the opinion of the investigator, would put the subject at risk by participation in the protocol.
  12. Evidence of dysplasia or history of (including lymphoma and leukemia).
  13. History of demyelinating disease (including myelitis) or neurologic symptoms suggestive of central nervous system [CNS] demyelinating disease.
  14. History of invasive fungal infection (e.g., listeriosis, histoplasmosis), active viral disorders, (HIV) infection.
  15. Positive test result.
  16. Chronic recurring infections or active TB.
  17. Screening laboratory and other analyses show any of the following abnormal results:

    • [ECG] - with clinically significant abnormalities;
    • (AST) or alanine transaminase (ALT) > 1.75 the upper limit of the reference range;
    • Total >=3 mg/dL;
    • Serum creatinine > 1.6 mg/dL (convert to mmol/L).
  18. Evidence of dysplasia or history of malignancy (including lymphoma and leukemia) other than a successfully treated non- cutaneous squamous cell or basal cell carcinoma.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Adalimumab

    Adalimumab 24 mg/m\^2 body surface area (BSA) up to a total dose of 20 mg administered every other week (eow) by parent or designee as a single dose via subcutaneous injection at approximately the same time of day, for a minimum of 24 weeks. Participants could continue in the study until age 4 and 15 kg (US and Puerto Rico) or for up to 1 additional year after reaching age 4 and 15 kg (EU). Visits beyond Week 24 occurred every 12 weeks for those participants who continued in the study.

    Drug: Adalimumab

Interventions

  • Adalimumab solution for injection for subcutaneous use.

    Also known as: Humira, ABT-D2E7

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. If an AE meets any of the following criteria, it is considered a serious adverse event (SAE): Results in death, is life-threatening, results in hospitalization or the prolongation of hospitalization, is a congenital anomaly or a persistent or significant disability/incapacity, or is an important medical event requiring medical or surgical intervention to prevent a serious outcome. A treatment-emergent AE (TEAE) is defined as any AE with onset or worsening reported by a participant from the time that the first dose of adalimumab is administered until 5 half-lives (70 days) have elapsed following discontinuation of adalimumab administration (total of 32.5 months).

    Time frame: TEAEs were collected from first dose of study drug until 70 days after the last dose of study drug and before start of commercial adalimumab or other biologics (32.5 months).

Secondary outcomes

  1. Mean Serum Adalimumab Trough Concentrations at Week 0, Week 12, and Week 24

    Adalimumab concentrations in serum were determined using a validated enzyme-linked immunoadsorbent assay (ELISA) method. The lower limit of quantitation (LLOQ) for adalimumab is 3.13 ng/mL.

    Time frame: Weeks 0, 12, and 24

  2. Hemoglobin: Mean Change From Baseline to Each Visit

    Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120

  3. Hematocrit: Mean Change From Baseline to Each Visit

    Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120

  4. Red Blood Cell (RBC) Count: Mean Change From Baseline to Each Visit

    Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120

  5. Platelets: Mean Change From Baseline to Each Visit

    Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120

  6. White Blood Cell (WBC) Count: Mean Change From Baseline to Each Visit

    Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120

  7. Neutrophils: Mean Change From Baseline to Each Visit

    Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120

  8. Lymphocytes: Mean Change From Baseline to Each Visit

    Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120

  9. Monocytes: Mean Change From Baseline to Each Visit

    Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120

  10. Eosinophils: Mean Change From Baseline to Each Visit

    Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120

  11. Basophils: Mean Change From Baseline to Each Visit

    Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120

  12. Alanine Aminotransferase (SGPT/ALT): Mean Change From Baseline to Each Visit

    Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120

  13. Aspartate Aminotransferase (SGOT/AST): Mean Change From Baseline to Each Visit

    Baseline is the last value prior to the first dose of study drug.Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120

  14. Alkaline Phosphatase (ALP): Mean Change From Baseline to Each Visit

    Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120

  15. Creatine Phosphokinase: Mean Change From Baseline to Each Visit

    Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120

  16. Total Bilirubin: Mean Change From Baseline to Each Visit

    Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120

  17. Creatinine: Mean Change From Baseline to Each Visit

    Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120

  18. Uric Acid: Mean Change From Baseline to Each Visit

    Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120

  19. Percentage of Participants Achieving Pediatric American College of Rheumatology (PedACR) 30% Response (PedACR30)

    The PedACR30 response is defined by the PedACR as ≥30% improvement in at least 3 of 6 JIA core set criteria, and ≥30% worsening in ≤1 of 6 JIA core set criteria. The 6 variables for the JIA core set criteria are Physician's Global Assessment (PGA) of participant's disease activity, Parent's Global Assessment of participant's disease activity, number of active joints (joints with swelling not due to deformity or joints with loss of passive motion \[LOM\] and joints with pain on passive motion \[POM\], tenderness, or both), number of joints with LOM, Disability Index of Child Health Assessment Questionnaire (DICHAQ), and C-reactive protein (CRP). Baseline is the last value prior to the first dose of study drug. Missing data were imputed up to Week 60 using last observation carried forward (LOCF) and non-responder imputation (NRI); observed values are presented for timepoints past Week 60. n=number of participants for either observed or imputed methods at given time point.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120

  20. Percentage of Participants Achieving Pediatric American College of Rheumatology (PedACR) 50% Response (PedACR50)

    The PedACR50 response is defined by the PedACR as ≥ 50% improvement in at least 3 of 6 JIA core set criteria, and ≥ 30% worsening in not more than 1 of 6 JIA core set criteria. The 6 variables for the JIA core set criteria include PGA of participant's disease activity, Parent's Global Assessment of participant's disease activity, number of active joints (joints with swelling not due to deformity or joints with LOM and joints with POM, tenderness, or both), number of joints with LOM, DICHAQ, and CRP. Baseline is the last value prior to the first dose of study drug. Missing data were imputed up to Week 60 using LOCF and by NRI; observed values are presented for timepoints past Week 60. n=number of participants for either observed or imputed methods at given time point.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120

  21. Percentage of Participants Achieving Pediatric American College of Rheumatology (PedACR) 70% Response (PedACR70)

    The PedACR70 response is defined by the PedACR as ≥ 70% improvement in at least 3 of 6 JIA core set criteria, and ≥ 30% worsening in not more than 1 of 6 JIA core set criteria. The 6 variables for the JIA core set criteria include PGA of participant's disease activity, Parent's Global Assessment of participant's disease activity, number of active joints (joints with swelling not due to deformity or joints with LOM and joints with POM, tenderness, or both), number of joints with LOM, DICHAQ, and CRP. Baseline is the last value prior to the first dose of study drug. Missing data were imputed up to Week 60 using LOCF and by NRI; observed values are presented for timepoints past Week 60. n=number of participants for either observed or imputed methods at given time point.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120

  22. Percentage of Participants Achieving Pediatric American College of Rheumatology (PedACR) 90% Response (PedACR90)

    The PedACR90 response is defined by the PedACR as ≥ 90% improvement in at least 3 of 6 JIA core set criteria, and ≥ 30% worsening in not more than 1 of 6 JIA core set criteria. The 6 variables for the JIA core set criteria include PGA of participant's disease activity, Parent's Global Assessment of participant's disease activity, number of active joints (joints with swelling not due to deformity or joints with LOM and joints with POM, tenderness, or both), number of joints with LOM, DICHAQ, and CRP. Baseline is the last value prior to the first dose of study drug. Missing data were imputed up to Week 60 using LOCF and by NRI; observed values are presented for timepoints past Week 60. n=number of participants for either observed or imputed methods at given time point.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120

  23. Physician's Global Assessment of Disease Activity: Mean Change From Baseline to Each Visit

    The physician's assessment of participant's overall disease activity on a visual analog scale (VAS). The VAS is a 100 mm scale, with scores ranging from 0 (very good) to 100 (very bad). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120

  24. Parent's Global Assessment of Disease Activity: Mean Change From Baseline to Each Visit

    The parent's assessment of how the participant's arthritis is doing overall on a VAS. The VAS is a 100 mm scale, with scores ranging from 0 (very good) to 100 (very bad). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120

  25. Disability Index of Child Health Assessment Questionnaire (DICHAQ): Mean Change From Baseline to Each Visit

    The DICHAQ is a self-reported participant-oriented outcome measure, calculated as the mean of the following 8 category scores (range: 0 to 3): Dressing and Grooming, Arising, Eating, Walking, Hygiene, Reach, Grip, and Activities. The score of each category is calculated as the maximum of the scores for the questions within that category. If aids and devices and/or help from another person are used for a category, a lower category score is adjusted to 2 for that category. A participant must have scores for at least 6 categories in order to compute the DICHAQ score. Total score is derived as average of all categories: 0 (no disability) to 3 (complete disability). Baseline is the last value prior to the first dose of study drug. Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120

  26. Active Joint Counts (AJC73): Mean Change From Baseline to Each Visit

    A joint assessment was recorded at all study visits to assess the number of active joints, with a total possible score of 0 (no active joints) to 73 (all active joints). Active joints are defined as joints with positive results for tenderness, swelling, pain on passive motion, or limitation of passive motion. Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

    Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, and 120

  27. Limitation of Passive Motion (LOM69) Joint Count: Mean Change From Baseline to Each Visit

    Sixty-nine joints were assessed by physical examination. The joints to be examined for LOM were the same as those examined for tenderness, except that the sacroiliac, sternoclavicular, and acromio clavicular joints were excluded. LOM of the joint was classified as present ("1"), absent ("0"), or replaced/injected ("9"). Scores range from 0 to 621, with higher scores representing higher disease activity. Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

    Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, and 120

  28. C-reactive Protein (CRP): Mean Change From Baseline to Each Visit

    CRP is a laboratory parameter and considered as an efficacy variable. CRP is a general marker of inflammation that is sensitive to acute changes in inflammatory response. CRP is reported using mg/dL. Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120

  29. Tender Joint Count (TJC75): Mean Change From Baseline to Each Visit

    Seventy-five joints or regions were assessed by pressure and joint manipulation on physical examination. Joint tenderness was classified as either present ("1"), absent ("0") or replaced/injected ("9"). Scores range from 0 to 675, with higher scores representing higher disease activity. Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

    Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, and 120

  30. Swollen Joint Count (SJC66): Mean Change From Baseline to Each Visit

    Sixty-six joints were assessed by physical examination. The joints to be examined for swelling were the same as those examined for tenderness, except that the hip, subtalar, sacroiliac, lumbar spine, thoracic spine, and cervical spine joints were excluded. Joint swelling was classified as present ("1"), absent ("0") or replaced/injected ("9"). Scores range from 0 to 594, with higher scores representing higher disease activity. Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

    Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, and 120

  31. Pain on Passive Motion (POM75) Joint Count: Mean Change From Baseline to Each Visit

    Seventy-five joints were assessed by physical examination. The joints to be examined for POM were the same as those examined for tenderness. POM of the joint was classified as present ("1"), absent ("0"), or replaced/injected ("9"). Scores range from 0 to 675, with higher scores representing higher disease activity. Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

    Time frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, and 120

  32. Child's Health Questionnaire Parent Form (CHQ-PF50) Global Health Category: Mean Change From Baseline to Each Visit

    The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120

  33. Child's Health Questionnaire Parent Form (CHQ-PF50) Physical Functioning Category: Mean Change From Baseline to Each Visit

    The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120.

  34. Child's Health Questionnaire Parent Form (CHQ-PF50) Role/Social Limitations/Emotional/Behavioral Category: Mean Change From Baseline to Each Visit

    The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120

  35. Child's Health Questionnaire Parent Form (CHQ-PF50) Role/Social Limitations - Physical Category: Mean Change From Baseline to Each Visit

    The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120

  36. Child's Health Questionnaire Parent Form (CHQ-PF50) Bodily Pain/Discomfort Category: Mean Change From Baseline to Each Visit

    The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120

  37. Child's Health Questionnaire Parent Form (CHQ-PF50) Behavior Category: Mean Change From Baseline to Each Visit

    The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120

  38. Child's Health Questionnaire Parent Form (CHQ-PF50) Global Behavior Item: Mean Change From Baseline to Each Visit

    The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120

  39. Child's Health Questionnaire Parent Form (CHQ-PF50) Mental Health Category: Mean Change From Baseline to Each Visit

    The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120

  40. Child's Health Questionnaire Parent Form (CHQ-PF50) Self Esteem Category: Mean Change From Baseline to Each Visit

    The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120

  41. Child's Health Questionnaire Parent Form (CHQ-PF50) General Health Perceptions Category: Mean Change From Baseline to Each Visit

    The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120

  42. Child's Health Questionnaire Parent Form (CHQ-PF50) Change in Health Category: Mean Change From Baseline to Each Visit

    The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120

  43. Child's Health Questionnaire Parent Form (CHQ-PF50) Parental Impact - Emotional Category: Mean Change From Baseline to Each Visit

    The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120

  44. Child's Health Questionnaire Parent Form (CHQ-PF50) Parental Impact - Time Category: Mean Change From Baseline to Each Visit

    The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120

  45. Child's Health Questionnaire Parent Form (CHQ-PF50) Family Activities Category: Mean Change From Baseline to Each Visit

    The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120

  46. Child's Health Questionnaire Parent Form (CHQ-PF50) Family Cohesion Category: Mean Change From Baseline to Each Visit

    The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

    Time frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120

07

Results

Posted Jan 26, 2016

Participant flow

Participants were enrolled at 14 investigative sites in the Czech Republic, France, Germany, and the United States.

Participant flow — Overall Study
MilestoneAdalimumab
Started32
Completed26
Not completed6
Withdrew: Loss of efficacy2
Withdrew: Withdrawal by subject3
Withdrew: Lost to follow-up1

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. If an AE meets any of the following criteria, it is considered a serious adverse event (SAE): Results in death, is life-threatening, results in hospitalization or the prolongation of hospitalization, is a congenital anomaly or a persistent or significant disability/incapacity, or is an important medical event requiring medical or surgical intervention to prevent a serious outcome. A treatment-emergent AE (TEAE) is defined as any AE with onset or worsening reported by a participant from the time that the first dose of adalimumab is administered until 5 half-lives (70 days) have elapsed following discontinuation of adalimumab administration (total of 32.5 months).

Time frame:
TEAEs were collected from first dose of study drug until 70 days after the last dose of study drug and before start of commercial adalimumab or other biologics (32.5 months).
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
participantsAdalimumab
Any Treatment-emergent AE29
Any Treatment-emergent SAE5
SecondaryMean Serum Adalimumab Trough Concentrations at Week 0, Week 12, and Week 24

Adalimumab concentrations in serum were determined using a validated enzyme-linked immunoadsorbent assay (ELISA) method. The lower limit of quantitation (LLOQ) for adalimumab is 3.13 ng/mL.

Time frame:
Weeks 0, 12, and 24
Reported as:
Mean · µg/mL
Mean Serum Adalimumab Trough Concentrations at Week 0, Week 12, and Week 24
µg/mLAdalimumab
Week 00 ± 0
Week 126.97 ± 5.69
Week 247.78 ± 5.85
SecondaryHemoglobin: Mean Change From Baseline to Each Visit

Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Reported as:
Mean · g/L
Hemoglobin: Mean Change From Baseline to Each Visit
g/LAdalimumab
Week 12 (n=29)6.7 ± 7.32
Week 24 (n=29)6.7 ± 9.76
Week 36 (n=25)5.5 ± 9.31
Week 48 (n=24)5.3 ± 10.68
Week 60 (n=21)6 ± 10.96
Week 72 (n=17)9.5 ± 10.65
Week 84 (n=16)10.5 ± 13.69
Week 96 (n=11)8.6 ± 9.99
Week 108 (n=9)7.7 ± 8.08
Week 120 (n=3)4.7 ± 2.89
SecondaryHematocrit: Mean Change From Baseline to Each Visit

Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Reported as:
Mean · Fraction
Hematocrit: Mean Change From Baseline to Each Visit
FractionAdalimumab
Week 12 (n=29)0.018 ± 0.0206
Week 24 (n=29)0.016 ± 0.0289
Week 36 (n=25)0.017 ± 0.0292
Week 48 (n=24)0.011 ± 0.0288
Week 60 (n=21)0.009 ± 0.0275
Week 72 (n=17)0.024 ± 0.0264
Week 84 (n=16)0.026 ± 0.0366
Week 96 (n=11)0.023 ± 0.0319
Week 108 (n=9)0.018 ± 0.0273
Week 120 (n=3)0.008 ± 0.0082
SecondaryRed Blood Cell (RBC) Count: Mean Change From Baseline to Each Visit

Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Reported as:
Mean · x10˄12/L
Red Blood Cell (RBC) Count: Mean Change From Baseline to Each Visit
x10˄12/LAdalimumab
Week 12 (n=29)0.15 ± 0.231
Week 24 (n=29)0.08 ± 0.308
Week 36 (n=25)0.098 ± 0.277
Week 48 (n=24)0.05 ± 0.213
Week 60 (n=21)0.07 ± 0.296
Week 72 (n=17)0.1 ± 0.187
Week 84 (n=16)0.06 ± 0.228
Week 96 (n=11)0.08 ± 0.343
Week 108 (n=9)0.1 ± 0.32
Week 120 (n=3)0.03 ± 0.153
SecondaryPlatelets: Mean Change From Baseline to Each Visit

Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Reported as:
Mean · x10˄9/L
Platelets: Mean Change From Baseline to Each Visit
x10˄9/LAdalimumab
Week 12 (n=29)-35 ± 145.44
Week 24 (n=29)-57.7 ± 140.82
Week 36 (n=25)-75.2 ± 148.51
Week 48 (n=23)-21 ± 174.17
Week 60 (n=21)-46.7 ± 125.71
Week 72 (n=17)-51.1 ± 111.11
Week 84 (n=15)-58.5 ± 127.29
Week 96 (n=11)-49.2 ± 142.73
Week 108 (n=9)-30.4 ± 137.84
Week 120 (n=3)20 ± 185.95
SecondaryWhite Blood Cell (WBC) Count: Mean Change From Baseline to Each Visit

Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Reported as:
Mean · x10^9/L
White Blood Cell (WBC) Count: Mean Change From Baseline to Each Visit
x10^9/LAdalimumab
Week 12 (n=29)0.19 ± 3.959
Week 24 (n=29)-0.25 ± 3.756
Week 36 (n=25)-0.42 ± 4.632
Week 48 (n=24)0.3 ± 4.804
Week 60 (n=21)0.25 ± 2.183
Week 72 (n=17)0.66 ± 3.225
Week 84 (n=16)0.18 ± 2.944
Week 96 (n=11)0.55 ± 2.757
Week 108 (n=9)-0.76 ± 4.166
Week 120 (n=3)1.8 ± 3.651
SecondaryNeutrophils: Mean Change From Baseline to Each Visit

Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Reported as:
Mean · x10˄9/L
Neutrophils: Mean Change From Baseline to Each Visit
x10˄9/LAdalimumab
Week 12 (n=29)-0.138 ± 2.9819
Week 24 (n=29)-0.619 ± 3.0082
Week 36 (n=25)-0.586 ± 3.7363
Week 48 (n=24)0.065 ± 3.4433
Week 60 (n=21)0.222 ± 2.0937
Week 72 (n=17)-0.169 ± 2.6167
Week 84 (n=16)-0.206 ± 2.0077
Week 96 (n=11)0.293 ± 2.511
Week 108 (n=9)-0.39 ± 3.1702
Week 120 (n=3)2.47 ± 3.2658
SecondaryLymphocytes: Mean Change From Baseline to Each Visit

Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Reported as:
Mean · x10˄9/L
Lymphocytes: Mean Change From Baseline to Each Visit
x10˄9/LAdalimumab
Week 12 (n=29)0.371 ± 2.3523
Week 24 (n=29)0.292 ± 1.9345
Week 36 (n=25)0.176 ± 1.962
Week 48 (n=24)0.186 ± 1.9584
Week 60 (n=21)-0.034 ± 1.6129
Week 72 (n=17)0.636 ± 1.7404
Week 84 (n=16)0.306 ± 1.5143
Week 96 (n=11)0.006 ± 1.9402
Week 108 (n=9)-0.46 ± 2.4315
Week 120 (n=3)-0.67 ± 1.8041
SecondaryMonocytes: Mean Change From Baseline to Each Visit

Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Reported as:
Mean · x10^9/L
Monocytes: Mean Change From Baseline to Each Visit
x10^9/LAdalimumab
Week 12 (n=29)-0.032 ± 0.3051
Week 24 (n=29)0.081 ± 0.4547
Week 36 (n=25)0.028 ± 0.2978
Week 48 (n=24)-0.006 ± 0.2718
Week 60 (n=21)0.08 ± 0.1831
Week 72 (n=17)0.113 ± 0.2054
Week 84 (n=16)0.061 ± 0.2594
Week 96 (n=11)0.089 ± 0.2295
Week 108 (n=9)0.096 ± 0.3248
Week 120 (n=3)0.057 ± 0.0777
SecondaryEosinophils: Mean Change From Baseline to Each Visit

Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Reported as:
Mean · x10^9/L
Eosinophils: Mean Change From Baseline to Each Visit
x10^9/LAdalimumab
Week 12 (n=29)-0.004 ± 0.1771
Week 24 (n=29)-0.006 ± 0.1545
Week 36 (n=25)-0.052 ± 0.1374
Week 48 (n=24)0.056 ± 0.2773
Week 60 (n=21)-0.015 ± 0.1363
Week 72 (n=17)0.069 ± 0.1886
Week 84 (n=16)0.016 ± 0.1631
Week 96 (n=11)0.158 ± 0.3207
Week 108 (n=9)-0.002 ± 0.0864
Week 120 (n=3)-0.063 ± 0.0929
SecondaryBasophils: Mean Change From Baseline to Each Visit

Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Reported as:
Mean · x10^9/L
Basophils: Mean Change From Baseline to Each Visit
x10^9/LAdalimumab
Week 12 (n=29)-0.012 ± 0.0299
Week 24 (n=29)-0.002 ± 0.0272
Week 36 (n=25)0.003 ± 0.0244
Week 48 (n=24)0.005 ± 0.0412
Week 60 (n=21)-0.003 ± 0.0256
Week 72 (n=17)0.007 ± 0.031
Week 84 (n=16)-0.001 ± 0.0171
Week 96 (n=11)-0.003 ± 0.0205
Week 108 (n=9)-0.001 ± 0.0117
Week 120 (n=3)0.003 ± 0.0306
SecondaryAlanine Aminotransferase (SGPT/ALT): Mean Change From Baseline to Each Visit

Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Reported as:
Mean · U/L
Alanine Aminotransferase (SGPT/ALT): Mean Change From Baseline to Each Visit
U/LAdalimumab
Week 12 (n=27)0.5 ± 9.96
Week 24 (n=28)-1.1 ± 17.13
Week 36 (n=25)0 ± 29.82
Week 48 (n=24)-4.5 ± 24.81
Week 60 (n=21)-2 ± 10.25
Week 72 (n=16)-1.8 ± 10.1
Week 84 (n=16)-0.5 ± 14.56
Week 96 (n=11)-3.9 ± 15.4
Week 108 (n=9)-2.4 ± 6.31
Week 120 (n=3)-14.3 ± 23.12
SecondaryAspartate Aminotransferase (SGOT/AST): Mean Change From Baseline to Each Visit

Baseline is the last value prior to the first dose of study drug.Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Reported as:
Mean · U/L
Aspartate Aminotransferase (SGOT/AST): Mean Change From Baseline to Each Visit
U/LAdalimumab
Week 12 (n=26)2.8 ± 7.56
Week 24 (n=28)-0.6 ± 8.82
Week 36 (n=25)2 ± 23.26
Week 48 (n=24)-0.7 ± 16.13
Week 60 (n=21)-0.4 ± 7.63
Week 72 (n=16)0.3 ± 7.36
Week 84 (n=16)-0.4 ± 6.89
Week 96 (n=10)1.5 ± 11.48
Week 108 (n=9)0.4 ± 6.21
Week 120 (n=3)-8.3 ± 11.93
SecondaryAlkaline Phosphatase (ALP): Mean Change From Baseline to Each Visit

Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Reported as:
Mean · U/L
Alkaline Phosphatase (ALP): Mean Change From Baseline to Each Visit
U/LAdalimumab
Week 12 (n=27)15.7 ± 64.65
Week 24 (n=28)10.6 ± 68.75
Week 36 (n=25)23.2 ± 73.28
Week 48 (n=24)21.7 ± 73.03
Week 60 (n=21)17.9 ± 85.55
Week 72 (n=16)17.9 ± 83.52
Week 84 (n=16)31.5 ± 89.3
Week 96 (n=11)59.4 ± 57.65
Week 108 (n=9)-6.3 ± 100.72
Week 120 (n=3)-72.3 ± 169.19
SecondaryCreatine Phosphokinase: Mean Change From Baseline to Each Visit

Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Reported as:
Mean · U/L
Creatine Phosphokinase: Mean Change From Baseline to Each Visit
U/LAdalimumab
Week 12 (n=27)17.2 ± 50.48
Week 24 (n=27)7 ± 30.79
Week 36 (n=25)24.8 ± 44.5
Week 48 (n=24)18.4 ± 54.02
Week 60 (n=21)26.6 ± 65.48
Week 72 (n=16)41.6 ± 40.63
Week 84 (n=16)36.4 ± 53.64
Week 96 (n=11)28.7 ± 41.79
Week 108 (n=9)7.2 ± 22.97
Week 120 (n=3)14 ± 40.73
SecondaryTotal Bilirubin: Mean Change From Baseline to Each Visit

Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Reported as:
Mean · µmol/L
Total Bilirubin: Mean Change From Baseline to Each Visit
µmol/LAdalimumab
Week 12 (n=27)1.2 ± 2.42
Week 24 (n=28)0.6 ± 1.59
Week 36 (n=25)0.6 ± 1.61
Week 48 (n=24)0.9 ± 2.4
Week 60 (n=21)1 ± 2.09
Week 72 (n=16)0.2 ± 1.25
Week 84 (n=16)0.5 ± 2.36
Week 96 (n=11)0.7 ± 1.62
Week 108 (n=9)1.1 ± 2.71
Week 120 (n=3)2.3 ± 0.58
SecondaryCreatinine: Mean Change From Baseline to Each Visit

Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Reported as:
Mean · µmol/L
Creatinine: Mean Change From Baseline to Each Visit
µmol/LAdalimumab
Week 12 (n=27)1.7 ± 5.98
Week 24 (n=28)0.5 ± 5.3
Week 36 (n=25)0.3 ± 5.84
Week 48 (n=24)2.5 ± 7.8
Week 60 (n=21)2.8 ± 5.79
Week 72 (n=16)3.4 ± 6.96
Week 84 (n=16)4 ± 6.37
Week 96 (n=11)3.2 ± 5.53
Week 108 (n=9)6.2 ± 6.7
Week 120 (n=3)8.7 ± 5.51
SecondaryUric Acid: Mean Change From Baseline to Each Visit

Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Reported as:
Mean · µmol/L
Uric Acid: Mean Change From Baseline to Each Visit
µmol/LAdalimumab
Week 12 (n=27)1.7 ± 48.24
Week 24 (n=27)6.5 ± 47.93
Week 36 (n=25)2.5 ± 41.77
Week 48 (n=24)5.6 ± 45.62
Week 60 (n=21)1.9 ± 30.86
Week 72 (n=16)-0.9 ± 43.53
Week 84 (n=16)-4.5 ± 46.76
Week 96 (n=11)13.3 ± 36.39
Week 108 (n=9)-10.1 ± 33.55
Week 120 (n=3)-7 ± 27.78
SecondaryPercentage of Participants Achieving Pediatric American College of Rheumatology (PedACR) 30% Response (PedACR30)

The PedACR30 response is defined by the PedACR as ≥30% improvement in at least 3 of 6 JIA core set criteria, and ≥30% worsening in ≤1 of 6 JIA core set criteria. The 6 variables for the JIA core set criteria are Physician's Global Assessment (PGA) of participant's disease activity, Parent's Global Assessment of participant's disease activity, number of active joints (joints with swelling not due to deformity or joints with loss of passive motion \[LOM\] and joints with pain on passive motion \[POM\], tenderness, or both), number of joints with LOM, Disability Index of Child Health Assessment Questionnaire (DICHAQ), and C-reactive protein (CRP). Baseline is the last value prior to the first dose of study drug. Missing data were imputed up to Week 60 using last observation carried forward (LOCF) and non-responder imputation (NRI); observed values are presented for timepoints past Week 60. n=number of participants for either observed or imputed methods at given time point.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Pediatric American College of Rheumatology (PedACR) 30% Response (PedACR30)
percentage of participantsAdalimumab
Week 12 Observed (n=31)93.5
Week 12 NRI (n=32)90.6
Week 12 LOCF (n=31)93.5
Week 24 Observed (n=30)90
Week 24 NRI (n=32)84.4
Week 24 LOCF (n=31)90.3
Week 36 Observed (n=27)92.6
Week 36 NRI (n=32)78.1
Week 36 LOCF (n=31)93.5
Week 48 Observed (n=24)83.3
Week 48 NRI (n=32)62.5
Week 48 LOCF (n=31)83.9
Week 60 Observed (n=20)90
Week 60 NRI (n=32)56.3
Week 60 LOCF (n=31)87.1
Week 72 Observed (n=17)100
Week 84 Observed (n=17)100
Week 96 Observed (n=13)92.3
Week 108 Observed (n=9)88.9
Week 120 Observed (n=3)100
SecondaryPercentage of Participants Achieving Pediatric American College of Rheumatology (PedACR) 50% Response (PedACR50)

The PedACR50 response is defined by the PedACR as ≥ 50% improvement in at least 3 of 6 JIA core set criteria, and ≥ 30% worsening in not more than 1 of 6 JIA core set criteria. The 6 variables for the JIA core set criteria include PGA of participant's disease activity, Parent's Global Assessment of participant's disease activity, number of active joints (joints with swelling not due to deformity or joints with LOM and joints with POM, tenderness, or both), number of joints with LOM, DICHAQ, and CRP. Baseline is the last value prior to the first dose of study drug. Missing data were imputed up to Week 60 using LOCF and by NRI; observed values are presented for timepoints past Week 60. n=number of participants for either observed or imputed methods at given time point.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Pediatric American College of Rheumatology (PedACR) 50% Response (PedACR50)
percentage of participantsAdalimumab
Week 12 Observed (n=31)90.3
Week 12 NRI (n=32)87.5
Week 12 LOCF (n=31)90.3
Week 24 Observed (n=30)83.3
Week 24 NRI (n=32)78.1
Week 24 LOCF (n=31)83.9
Week 36 Observed (n=27)88.9
Week 36 NRI (n=32)75
Week 36 LOCF (n=31)90.3
Week 48 Observed (n=24)79.2
Week 48 NRI (n=32)59.4
Week 48 LOCF (n=31)80.6
Week 60 Observed (n=20)80
Week 60 NRI (n=32)50
Week 60 LOCF (n=31)80.6
Week 72 Observed (n=17)100
Week 84 Observed (n=17)94.1
Week 96 Observed (n=13)92.3
Week 108 Observed (n=9)88.9
Week 120 Observed (n=3)100
SecondaryPercentage of Participants Achieving Pediatric American College of Rheumatology (PedACR) 70% Response (PedACR70)

The PedACR70 response is defined by the PedACR as ≥ 70% improvement in at least 3 of 6 JIA core set criteria, and ≥ 30% worsening in not more than 1 of 6 JIA core set criteria. The 6 variables for the JIA core set criteria include PGA of participant's disease activity, Parent's Global Assessment of participant's disease activity, number of active joints (joints with swelling not due to deformity or joints with LOM and joints with POM, tenderness, or both), number of joints with LOM, DICHAQ, and CRP. Baseline is the last value prior to the first dose of study drug. Missing data were imputed up to Week 60 using LOCF and by NRI; observed values are presented for timepoints past Week 60. n=number of participants for either observed or imputed methods at given time point.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Pediatric American College of Rheumatology (PedACR) 70% Response (PedACR70)
percentage of participantsAdalimumab
Week 12 Observed (n=31)61.3
Week 12 NRI (n=32)59.4
Week 12 LOCF (n=31)61.3
Week 24 Observed (n=30)73.3
Week 24 NRI (n=32)68.8
Week 24 LOCF (n=31)74.2
Week 36 Observed (n=27)66.7
Week 36 NRI (n=32)56.3
Week 36 LOCF (n=31)67.7
Week 48 Observed (n=24)75
Week 48 NRI (n=32)56.3
Week 48 LOCF (n=31)74.2
Week 60 Observed (n=20)70
Week 60 NRI (n=32)43.8
Week 60 LOCF (n=31)71
Week 72 Observed (n=17)76.5
Week 84 Observed (n=17)82.4
Week 96 Observed (n=13)76.9
Week 108 Observed (n=9)77.8
Week 120 Observed (n=3)100
SecondaryPercentage of Participants Achieving Pediatric American College of Rheumatology (PedACR) 90% Response (PedACR90)

The PedACR90 response is defined by the PedACR as ≥ 90% improvement in at least 3 of 6 JIA core set criteria, and ≥ 30% worsening in not more than 1 of 6 JIA core set criteria. The 6 variables for the JIA core set criteria include PGA of participant's disease activity, Parent's Global Assessment of participant's disease activity, number of active joints (joints with swelling not due to deformity or joints with LOM and joints with POM, tenderness, or both), number of joints with LOM, DICHAQ, and CRP. Baseline is the last value prior to the first dose of study drug. Missing data were imputed up to Week 60 using LOCF and by NRI; observed values are presented for timepoints past Week 60. n=number of participants for either observed or imputed methods at given time point.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Pediatric American College of Rheumatology (PedACR) 90% Response (PedACR90)
percentage of participantsAdalimumab
Week 12 Observed (n=31)38.7
Week 12 NRI (n=32)37.5
Week 12 LOCF (n=31)38.7
Week 24 Observed (n=30)36.7
Week 24 NRI (n=32)34.4
Week 24 LOCF (n=31)35.5
Week 36 Observed (n=27)51.9
Week 36 NRI (n=32)43.8
Week 36 LOCF (n=31)51.6
Week 48 Observed (n=24)62.5
Week 48 NRI (n=32)46.9
Week 48 LOCF (n=31)58.1
Week 60 Observed (n=20)50
Week 60 NRI (n=32)31.3
Week 60 LOCF (n=31)51.6
Week 72 Observed (n=17)64.7
Week 84 Observed (n=17)64.7
Week 96 Observed (n=13)61.5
Week 108 Observed (n=9)66.7
Week 120 Observed (n=3)100
SecondaryPhysician's Global Assessment of Disease Activity: Mean Change From Baseline to Each Visit

The physician's assessment of participant's overall disease activity on a visual analog scale (VAS). The VAS is a 100 mm scale, with scores ranging from 0 (very good) to 100 (very bad). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Reported as:
Mean · units on a scale
Physician's Global Assessment of Disease Activity: Mean Change From Baseline to Each Visit
units on a scaleAdalimumab
Week 12 (n=31)-41.4 ± 21.2
Week 24 (n=30)-45.3 ± 21.32
Week 36 (n=28)-43 ± 23.9
Week 48 (n=24)-46.5 ± 18.35
Week 60 (n=21)-42.7 ± 28.17
Week 72 (n=17)-51.1 ± 19.53
Week 84 (n=17)-50.5 ± 16.77
Week 96 (n=13)-47.5 ± 24.42
Week 108 (n=9)-48.3 ± 28.24
Week 120 (n=3)-56.3 ± 5.13
SecondaryParent's Global Assessment of Disease Activity: Mean Change From Baseline to Each Visit

The parent's assessment of how the participant's arthritis is doing overall on a VAS. The VAS is a 100 mm scale, with scores ranging from 0 (very good) to 100 (very bad). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Reported as:
Mean · units on a scale
Parent's Global Assessment of Disease Activity: Mean Change From Baseline to Each Visit
units on a scaleAdalimumab
Week 12 (n=31)-28.1 ± 29.91
Week 24 (n=30)-32.2 ± 29.74
Week 36 (n=27)-35.1 ± 27.42
Week 48 (n=24)-35.6 ± 32.19
Week 60 (n=21)-34.5 ± 33.31
Week 72 (n=17)-43.8 ± 25.58
Week 84 (n=17)-42.6 ± 28.62
Week 96 (n=13)-45.8 ± 29.1
Week 108 (n=9)-39.9 ± 37.54
Week 120 (n=3)-47.7 ± 34.96
SecondaryDisability Index of Child Health Assessment Questionnaire (DICHAQ): Mean Change From Baseline to Each Visit

The DICHAQ is a self-reported participant-oriented outcome measure, calculated as the mean of the following 8 category scores (range: 0 to 3): Dressing and Grooming, Arising, Eating, Walking, Hygiene, Reach, Grip, and Activities. The score of each category is calculated as the maximum of the scores for the questions within that category. If aids and devices and/or help from another person are used for a category, a lower category score is adjusted to 2 for that category. A participant must have scores for at least 6 categories in order to compute the DICHAQ score. Total score is derived as average of all categories: 0 (no disability) to 3 (complete disability). Baseline is the last value prior to the first dose of study drug. Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Reported as:
Mean · units on a scale
Disability Index of Child Health Assessment Questionnaire (DICHAQ): Mean Change From Baseline to Each Visit
units on a scaleAdalimumab
Week 12 (n=31)-0.5 ± 0.64
Week 24 (n=30)-0.5 ± 0.69
Week 36 (n=27)-0.6 ± 0.7
Week 48 (n=24)-0.6 ± 0.68
Week 60 (n=21)-0.6 ± 0.71
Week 72 (n=16)-0.9 ± 0.64
Week 84 (n=17)-0.9 ± 0.68
Week 96 (n=13)-0.8 ± 0.56
Week 108 (n=9)-0.8 ± 0.63
Week 120 (n=3)-0.8 ± 1.09
SecondaryActive Joint Counts (AJC73): Mean Change From Baseline to Each Visit

A joint assessment was recorded at all study visits to assess the number of active joints, with a total possible score of 0 (no active joints) to 73 (all active joints). Active joints are defined as joints with positive results for tenderness, swelling, pain on passive motion, or limitation of passive motion. Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

Time frame:
Baseline and Weeks 2, 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Reported as:
Mean · units on a scale
Active Joint Counts (AJC73): Mean Change From Baseline to Each Visit
units on a scaleAdalimumab
Week 2 (n=32)-5 ± 6.58
Week 4 (n=32)-6.1 ± 6.69
Week 8 (n=32)-7 ± 5.24
Week 12 (n=31)-7.3 ± 4.52
Week 16 (n=31)-7.1 ± 5.87
Week 20 (n=29)-8 ± 5.68
Week 24 (n=30)-7.2 ± 5.6
Week 36 (n=28)-7.3 ± 5.21
Week 48 (n=24)-8 ± 5.5
Week 60 (n=20)-9.5 ± 7.5
Week 72 (n=17)-10.2 ± 6.64
Week 84 (n=17)-10.4 ± 7.57
Week 96 (n=13)-8.9 ± 7.04
Week 108 (n=9)-5.9 ± 3.33
Week 120 (n=3)-7.3 ± 2.08
SecondaryLimitation of Passive Motion (LOM69) Joint Count: Mean Change From Baseline to Each Visit

Sixty-nine joints were assessed by physical examination. The joints to be examined for LOM were the same as those examined for tenderness, except that the sacroiliac, sternoclavicular, and acromio clavicular joints were excluded. LOM of the joint was classified as present ("1"), absent ("0"), or replaced/injected ("9"). Scores range from 0 to 621, with higher scores representing higher disease activity. Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

Time frame:
Baseline and Weeks 2, 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Reported as:
Mean · units on a scale
Limitation of Passive Motion (LOM69) Joint Count: Mean Change From Baseline to Each Visit
units on a scaleAdalimumab
Week 2 (n=32)-4.5 ± 7.14
Week 4 (n=32)-5.4 ± 6.48
Week 8 (n=32)-5.3 ± 5.02
Week 12 (n=31)-5.6 ± 4.8
Week 16 (n=31)-6.3 ± 6.31
Week 20 (n=29)-6.8 ± 6.63
Week 24 (n=30)-5.6 ± 5.54
Week 36 (n=28)-5.1 ± 5.29
Week 48 (n=24)-5.5 ± 7.06
Week 60 (n=20)-5.5 ± 8.31
Week 72 (n=17)-6.9 ± 7.84
Week 84 (n=17)-8.4 ± 6.9
Week 96 (n=13)-7.5 ± 6.73
Week 108 (n=9)-5.2 ± 3.96
Week 120 (n=3)-6 ± 2.65
SecondaryC-reactive Protein (CRP): Mean Change From Baseline to Each Visit

CRP is a laboratory parameter and considered as an efficacy variable. CRP is a general marker of inflammation that is sensitive to acute changes in inflammatory response. CRP is reported using mg/dL. Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Reported as:
Mean · mg/dL
C-reactive Protein (CRP): Mean Change From Baseline to Each Visit
mg/dLAdalimumab
Week 12 (n=28)-0.6 ± 2.65
Week 24 (n=28)-0.2 ± 3.2
Week 36 (n=25)-0.4 ± 3.08
Week 48 (n=23)0.4 ± 2.68
Week 60 (n=20)-0.3 ± 1.83
Week 72 (n=17)-0.7 ± 1.25
Week 84 (n=17)-0.7 ± 1.47
Week 96 (n=12)0.1 ± 1.6
Week 108 (n=9)0.2 ± 1.93
Week 120 (n=3)0.3 ± 0.28
SecondaryTender Joint Count (TJC75): Mean Change From Baseline to Each Visit

Seventy-five joints or regions were assessed by pressure and joint manipulation on physical examination. Joint tenderness was classified as either present ("1"), absent ("0") or replaced/injected ("9"). Scores range from 0 to 675, with higher scores representing higher disease activity. Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

Time frame:
Baseline and Weeks 2, 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Reported as:
Mean · units on a scale
Tender Joint Count (TJC75): Mean Change From Baseline to Each Visit
units on a scaleAdalimumab
Week 2 (n=32)-2.3 ± 4.62
Week 4 (n=32)-2.8 ± 4.48
Week 8 (n=32)-3.1 ± 4.31
Week 12 (n=31)-2.7 ± 5.09
Week 16 (n=31)-3.5 ± 4.77
Week 20 (n=29)-3.9 ± 5.09
Week 24 (n=30)-3 ± 5.54
Week 36 (n=28)-2.9 ± 5.65
Week 48 (n=24)-4.4 ± 4.85
Week 60 (n=20)-4.5 ± 5.85
Week 72 (n=17)-5.3 ± 5.53
Week 84 (n=17)-4.8 ± 5.2
Week 96 (n=13)-4 ± 5.46
Week 108 (n=9)-1.1 ± 4.73
Week 120 (n=3)-1.3 ± 2.31
SecondarySwollen Joint Count (SJC66): Mean Change From Baseline to Each Visit

Sixty-six joints were assessed by physical examination. The joints to be examined for swelling were the same as those examined for tenderness, except that the hip, subtalar, sacroiliac, lumbar spine, thoracic spine, and cervical spine joints were excluded. Joint swelling was classified as present ("1"), absent ("0") or replaced/injected ("9"). Scores range from 0 to 594, with higher scores representing higher disease activity. Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

Time frame:
Baseline and Weeks 2, 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Reported as:
Mean · units on a scale
Swollen Joint Count (SJC66): Mean Change From Baseline to Each Visit
units on a scaleAdalimumab
Week 2 (n=32)-4.5 ± 6.46
Week 4 (n=32)-5.3 ± 6.63
Week 8 (n=32)-6 ± 5.32
Week 12 (n=31)-6.2 ± 4.24
Week 16 (n=31)-6.1 ± 6.59
Week 20 (n=29)-6.9 ± 5.62
Week 24 (n=30)-6.3 ± 5.83
Week 36 (n=28)-6.2 ± 4.73
Week 48 (n=24)-6.7 ± 5.34
Week 60 (n=20)-8.4 ± 7.15
Week 72 (n=17)-8.9 ± 6.06
Week 84 (n=17)-9.4 ± 7.15
Week 96 (n=13)-8.5 ± 6.89
Week 108 (n=9)-5.8 ± 3.31
Week 120 (n=3)-7.3 ± 2.08
SecondaryPain on Passive Motion (POM75) Joint Count: Mean Change From Baseline to Each Visit

Seventy-five joints were assessed by physical examination. The joints to be examined for POM were the same as those examined for tenderness. POM of the joint was classified as present ("1"), absent ("0"), or replaced/injected ("9"). Scores range from 0 to 675, with higher scores representing higher disease activity. Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

Time frame:
Baseline and Weeks 2, 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Reported as:
Mean · units on a scale
Pain on Passive Motion (POM75) Joint Count: Mean Change From Baseline to Each Visit
units on a scaleAdalimumab
Week 2 (n=32)-3.3 ± 4.5
Week 4 (n=32)-4 ± 4.01
Week 8 (n=32)-4.6 ± 5.17
Week 12 (n=31)-4.9 ± 4.59
Week 16 (n=31)-4.9 ± 4.6
Week 20 (n=29)-5.4 ± 4.81
Week 24 (n=30)-4.1 ± 7.32
Week 36 (n=28)-4.3 ± 7.34
Week 48 (n=24)-5.8 ± 4.42
Week 60 (n=20)-5.9 ± 5.25
Week 72 (n=17)-6.4 ± 5.41
Week 84 (n=17)-6.1 ± 5.34
Week 96 (n=13)5.7 ± 5.12
Week 108 (n=9)-3.6 ± 5.85
Week 120 (n=3)-5.3 ± 1.53
SecondaryChild's Health Questionnaire Parent Form (CHQ-PF50) Global Health Category: Mean Change From Baseline to Each Visit

The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Reported as:
Mean · units on a scale
Child's Health Questionnaire Parent Form (CHQ-PF50) Global Health Category: Mean Change From Baseline to Each Visit
units on a scaleAdalimumab
Week 12 (n=29)17.1 ± 29.48
Week 24 (n=28)24.3 ± 25.77
Week 36 (n=24)25 ± 27.27
Week 48 (n=22)30.9 ± 23.79
Week 60 (n=19)21.8 ± 27.35
Week 72 (n=17)31.5 ± 24.86
Week 84 (n=17)26.2 ± 25.89
Week 96 (n=11)32.7 ± 20.66
Week 108 (n=8)36.9 ± 19.99
Week 120 (n=3)45 ± 17.32
SecondaryChild's Health Questionnaire Parent Form (CHQ-PF50) Physical Functioning Category: Mean Change From Baseline to Each Visit

The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120.
Reported as:
Mean · units on a scale
Child's Health Questionnaire Parent Form (CHQ-PF50) Physical Functioning Category: Mean Change From Baseline to Each Visit
units on a scaleAdalimumab
Week 12 (n=31)30.6 ± 32.14
Week 24 (n=30)31.6 ± 31.91
Week 36 (n=27)36.4 ± 31.26
Week 48 (n=23)31.5 ± 28.39
Week 60 (n=21)29 ± 32.3
Week 72 (n=16)40.6 ± 27
Week 84 (n=17)40 ± 30.44
Week 96 (n=13)34.3 ± 27.88
Week 108 (n=9)37 ± 27.92
Week 120 (n=3)53.7 ± 8.49
SecondaryChild's Health Questionnaire Parent Form (CHQ-PF50) Role/Social Limitations/Emotional/Behavioral Category: Mean Change From Baseline to Each Visit

The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Reported as:
Mean · units on a scale
Child's Health Questionnaire Parent Form (CHQ-PF50) Role/Social Limitations/Emotional/Behavioral Category: Mean Change From Baseline to Each Visit
units on a scaleAdalimumab
Week 12 (n=23)20.8 ± 32.53
Week 24 (n=22)17.7 ± 29.43
Week 36 (n=20)17.2 ± 25.86
Week 48 (n=18)16 ± 27.28
Week 60 (n=16)20.8 ± 31.91
Week 72 (n=13)26.5 ± 32.25
Week 84 (n=13)20.5 ± 33.29
Week 96 (n=9)30.9 ± 32.76
Week 108 (n=7)23.8 ± 25.2
Week 120 (n=2)33.3 ± 47.14
SecondaryChild's Health Questionnaire Parent Form (CHQ-PF50) Role/Social Limitations - Physical Category: Mean Change From Baseline to Each Visit

The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Reported as:
Mean · units on a scale
Child's Health Questionnaire Parent Form (CHQ-PF50) Role/Social Limitations - Physical Category: Mean Change From Baseline to Each Visit
units on a scaleAdalimumab
Week 12 (n=21)28.6 ± 32.97
Week 24 (n=20)31.7 ± 35
Week 36 (n=18)30.6 ± 39.3
Week 48 (n=17)27.5 ± 37.24
Week 60 (n=15)34.4 ± 39.07
Week 72 (n=12)36.1 ± 41.34
Week 84 (n=12)34.7 ± 43.5
Week 96 (n=8)41.7 ± 37.8
Week 108 (n=6)47.2 ± 37.14
Week 120 (n=1)66.7 ± 0
SecondaryChild's Health Questionnaire Parent Form (CHQ-PF50) Bodily Pain/Discomfort Category: Mean Change From Baseline to Each Visit

The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Reported as:
Mean · units on a scale
Child's Health Questionnaire Parent Form (CHQ-PF50) Bodily Pain/Discomfort Category: Mean Change From Baseline to Each Visit
units on a scaleAdalimumab
Week 12 (n=30)35 ± 30.6
Week 24 (n=29)36.2 ± 32.99
Week 36 (n=26)38.8 ± 27.76
Week 48 (n=23)41.7 ± 29.64
Week 60 (n=20)39 ± 34.78
Week 72 (n=17)48.2 ± 20.38
Week 84 (n=17)41.2 ± 25.47
Week 96 (n=13)42.3 ± 23.51
Week 108 (n=9)41.1 ± 37.56
Week 120 (n=3)50 ± 17.32
SecondaryChild's Health Questionnaire Parent Form (CHQ-PF50) Behavior Category: Mean Change From Baseline to Each Visit

The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Reported as:
Mean · units on a scale
Child's Health Questionnaire Parent Form (CHQ-PF50) Behavior Category: Mean Change From Baseline to Each Visit
units on a scaleAdalimumab
Week 12 (n=29)5.6 ± 15.78
Week 24 (n=28)4.2 ± 13.58
Week 36 (n=27)0.4 ± 16.87
Week 48 (n=24)3.6 ± 17.04
Week 60 (n=21)-0.3 ± 13.95
Week 72 (n=17)0.1 ± 16.44
Week 84 (n=17)1.5 ± 13.97
Week 96 (n=13)7.1 ± 11.81
Week 108 (n=9)8.9 ± 10.46
Week 120 (n=3)-6.1 ± 31.28
SecondaryChild's Health Questionnaire Parent Form (CHQ-PF50) Global Behavior Item: Mean Change From Baseline to Each Visit

The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Reported as:
Mean · units on a scale
Child's Health Questionnaire Parent Form (CHQ-PF50) Global Behavior Item: Mean Change From Baseline to Each Visit
units on a scaleAdalimumab
Week 12 (n=19)4.5 ± 18.17
Week 24 (n=19)10.8 ± 17.66
Week 36 (n=18)9.2 ± 25.04
Week 48 (n=16)4.1 ± 18.55
Week 60 (n=13)-3.5 ± 20.35
Week 72 (n=10)2 ± 15.31
Week 84 (n=11)-5 ± 14.32
Week 96 (n=9)0 ± 17.68
Week 108 (n=6)-4.2 ± 10.21
Week 120 (n=1)-25 ± 0
SecondaryChild's Health Questionnaire Parent Form (CHQ-PF50) Mental Health Category: Mean Change From Baseline to Each Visit

The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Reported as:
Mean · units on a scale
Child's Health Questionnaire Parent Form (CHQ-PF50) Mental Health Category: Mean Change From Baseline to Each Visit
units on a scaleAdalimumab
Week 12 (n=31)3.5 ± 11.12
Week 24 (n=30)3.5 ± 10.76
Week 36 (n=27)4.1 ± 14.01
Week 48 (n=24)5.4 ± 11.88
Week 60 (n=21)2.1 ± 14.02
Week 72 (n=17)5 ± 12.37
Week 84 (n=17)2.6 ± 8.5
Week 96 (n=13)4.2 ± 11.88
Week 108 (n=9)-0.8 ± 15
Week 120 (n=3)-3.3 ± 20.21
SecondaryChild's Health Questionnaire Parent Form (CHQ-PF50) Self Esteem Category: Mean Change From Baseline to Each Visit

The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Reported as:
Mean · units on a scale
Child's Health Questionnaire Parent Form (CHQ-PF50) Self Esteem Category: Mean Change From Baseline to Each Visit
units on a scaleAdalimumab
Week 12 (n=23)10.6 ± 23.91
Week 24 (n=22)10.5 ± 24.75
Week 36 (n=19)16.8 ± 22.02
Week 48 (n=16)15.2 ± 22.6
Week 60 (n=14)10.2 ± 22.53
Week 72 (n=13)-2.8 ± 31.78
Week 84 (n=13)9.4 ± 18.52
Week 96 (n=9)6.9 ± 19.87
Week 108 (n=6)-4.2 ± 10.87
Week 120 (n=1)4.2 ± 0
SecondaryChild's Health Questionnaire Parent Form (CHQ-PF50) General Health Perceptions Category: Mean Change From Baseline to Each Visit

The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Reported as:
Mean · units on a scale
Child's Health Questionnaire Parent Form (CHQ-PF50) General Health Perceptions Category: Mean Change From Baseline to Each Visit
units on a scaleAdalimumab
Week 12 (n=26)0.7 ± 14.27
Week 24 (n=25)3.8 ± 14.98
Week 36 (n=22)6.2 ± 15.99
Week 48 (n=19)7.2 ± 13.36
Week 60 (n=18)0.7 ± 10.65
Week 72 (n=15)9.1 ± 10.1
Week 84 (n=15)7.2 ± 13.03
Week 96 (n=11)10.9 ± 16
Week 108 (n=7)9 ± 16.61
Week 120 (n=3)4.7 ± 12.92
SecondaryChild's Health Questionnaire Parent Form (CHQ-PF50) Change in Health Category: Mean Change From Baseline to Each Visit

The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Reported as:
Mean · units on a scale
Child's Health Questionnaire Parent Form (CHQ-PF50) Change in Health Category: Mean Change From Baseline to Each Visit
units on a scaleAdalimumab
Week 12 (n=30)1.4 ± 1.75
Week 24 (n=29)1.7 ± 1.67
Week 36 (n=25)1.7 ± 1.8
Week 48 (n=22)1.7 ± 2.4
Week 60 (n=20)1.3 ± 2.57
Week 72 (n=16)1.6 ± 2.13
Week 84(n=16)1.3 ± 1.98
Week 96 (n=12)1.5 ± 2.02
Week 108 (n=8)0.9 ± 2.7
Week 120 (n=3)2.3 ± 0.58
SecondaryChild's Health Questionnaire Parent Form (CHQ-PF50) Parental Impact - Emotional Category: Mean Change From Baseline to Each Visit

The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Reported as:
Mean · units on a scale
Child's Health Questionnaire Parent Form (CHQ-PF50) Parental Impact - Emotional Category: Mean Change From Baseline to Each Visit
units on a scaleAdalimumab
Week 12 (n=30)11.4 ± 26.12
Week 24 (n=28)19 ± 28.59
Week 36 (n=26)29.2 ± 33.1
Week 48 (n=23)34.1 ± 33.98
Week 60 (n=20)31.7 ± 32.4
Week 72 (n=16)34.4 ± 36.37
Week 84 (n=16)27.6 ± 41.69
Week 96 (n=11)43.9 ± 40.15
Week 108 (n=8)46.9 ± 40.81
Week 120 (n=2)62.5 ± 41.25
SecondaryChild's Health Questionnaire Parent Form (CHQ-PF50) Parental Impact - Time Category: Mean Change From Baseline to Each Visit

The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Reported as:
Mean · units on a scale
Child's Health Questionnaire Parent Form (CHQ-PF50) Parental Impact - Time Category: Mean Change From Baseline to Each Visit
units on a scaleAdalimumab
Week 12 (n=30)4.6 ± 24.5
Week 24 (n=28)13.5 ± 28.59
Week 36 (n=26)21.8 ± 24.24
Week 48 (n=23)18.4 ± 24.76
Week 60 (n=20)13.3 ± 31.55
Week 72 (n=16)22.2 ± 30.09
Week 84 (n=16)17.4 ± 35.13
Week 96 (n=12)20.4 ± 27.15
Week 108 (n=8)15.3 ± 25.85
Week 120 (n=2)55.6 ± 62.85
SecondaryChild's Health Questionnaire Parent Form (CHQ-PF50) Family Activities Category: Mean Change From Baseline to Each Visit

The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Reported as:
Mean · units on a scale
Child's Health Questionnaire Parent Form (CHQ-PF50) Family Activities Category: Mean Change From Baseline to Each Visit
units on a scaleAdalimumab
Week 12 (n=30)8.3 ± 28.41
Week 24 (n=28)17.6 ± 24.15
Week 36 (n=26)20 ± 28.5
Week 48 (n=23)16.8 ± 26.43
Week 60 (n=20)14.8 ± 30.9
Week 72 (n=16)17.2 ± 31.43
Week 84 (n=16)18.2 ± 30.27
Week 96 (n=12)19.4 ± 27.6
Week 108 (n=8)20.8 ± 29.38
Week 120 (n=2)68.8 ± 20.62
SecondaryChild's Health Questionnaire Parent Form (CHQ-PF50) Family Cohesion Category: Mean Change From Baseline to Each Visit

The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

Time frame:
Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Reported as:
Mean · units on a scale
Child's Health Questionnaire Parent Form (CHQ-PF50) Family Cohesion Category: Mean Change From Baseline to Each Visit
units on a scaleAdalimumab
Week 12 (n=30)2.5 ± 14
Week 24 (n=28)4.3 ± 23.28
Week 36 (n=26)5.6 ± 20.66
Week 48 (n=23)3.7 ± 15.61
Week 60 (n=20)4.8 ± 16.66
Week 72 (n=16)7.2 ± 29.15
Week 84 (n=16)8.4 ± 39.19
Week 96 (n=12)18.8 ± 35.36
Week 108 (n=8)19.4 ± 35.3
Week 120 (n=2)-27.5 ± 38.89

Adverse events

Collected over TEAEs were collected from first dose of study drug until 70 days after the last dose of study drug and before start of commercial adalimumab or other biologics (32.5 months); SAEs were collected from the time informed consent was obtained (33.5 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adalimumab—5/32 (15.6%)27/32 (84.4%)
Most frequent serious events
Most frequent serious events
EventAdalimumab
Dental cariesGastrointestinal disorders1/32
Juvenile arthritisMusculoskeletal and connective tissue disorders1/32
Type 1 diabetes mellitusMetabolism and nutrition disorders1/32
Gastroenteritis rotavirusInfections and infestations1/32
VaricellaInfections and infestations1/32
Most frequent other events
Showing 10 of 26
Most frequent other events
EventAdalimumab
NasopharyngitisInfections and infestations8/32
PyrexiaGeneral disorders7/32
CoughRespiratory, thoracic and mediastinal disorders6/32
RhinorrhoeaRespiratory, thoracic and mediastinal disorders6/32
BronchitisInfections and infestations6/32
Upper respiratory tract infectionInfections and infestations6/32
VomitingGastrointestinal disorders5/32
Otitis mediaInfections and infestations5/32
DiarrhoeaGastrointestinal disorders4/32
RashSkin and subcutaneous tissue disorders4/32

Baseline characteristics

Age, Continuous
Age, Continuous(years)Adalimumab
Mean3.04 ± 0.723
Age, Customized
Age, Customized(participants)Adalimumab
< 4 years28
≥ 4 years4
Sex: Female, Male
Sex: Female, Male(Participants)Adalimumab
Female28
Male4
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Horneff G, Seyger MMB, Arikan D, Kalabic J, Anderson JK, Lazar A, Williams DA, Wang C, Tarzynski-Potempa R, Hyams JS. Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn's Disease. J Pediatr. 2018 Oct;201:166-175.e3. doi: 10.1016/j.jpeds.2018.05.042. Epub 2018 Jul 25. PubMed 30054164 ↗
  • Kingsbury DJ, Bader-Meunier B, Patel G, Arora V, Kalabic J, Kupper H. Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years. Clin Rheumatol. 2014;33(10):1433-41. doi: 10.1007/s10067-014-2498-1. Epub 2014 Feb 2. PubMed 24487484 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2009, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2016, 2 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2008
First posted
Oct 20, 2008
Start
Mar 2009
Primary completionActual
Mar 2013
CompletionActual
Mar 2013
Results first posted
Jan 26, 2016
Last update
Jan 26, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00775437
Responsible party
Sponsor
First posted
Oct 20, 2008
Start date
Mar 2009
Primary completion
Mar 2013
Completion
Mar 2013
Results posted
Jan 26, 2016
Last update
Jan 26, 2016

Study contacts

Aileen L. Pangan, MD
study director · AbbVie

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion